MedPath

Comparison of 10 days nonbismuth-containing quadruple therapy and modified sequential therapy for Helicobacter pylori eradication (Hybrid study): Randomised controlled trial

Not Applicable
Completed
Conditions
Diseases of the digestive system
Registration Number
KCT0000728
Lead Sponsor
Kyungpook National University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
480
Inclusion Criteria

1) Either sex in age of 18 to 85
2) Among patients with active/inactive peptic ulcer diagnosed from endoscopy, those who have come up with benign helicobacter after an examination (a rapid urease test)
3) Among patients with no organic disorders from endoscopy but with indigestion, those who have been diagnosed with benign helicobacter after an examination (a rapid urease test) and those who are willing to get a bacteria-removal treatment
4) Among patients who received endoscopic mucosal resection or submucosal dissection to treat gastric adenoma or early gastric cancer, those with benign helicobacter diagnosed from an examination
5) Those who have signed a written subject consent to join the experimentation

Exclusion Criteria

1) Patients who have refused to participate in the experimentation
2) Patients who have been cured by the helicobacter eradication
3) Patients who have taken drugs for the last two weeks which would affect a bacteria examination and treatment (proton pump inhibitor, antibiotics, H2-receptor antagonist and bismuth)
4) Patients who are on steroids, aspirin and antithrombotic
5) Patients who have gone through a gastric operation (a gastric mucosal resection excluded)
6) Patients with severe heart disease, lung disease, hormonal disorder
7) Patients with severe problems in kidney and liver
8) Patients with blood disease
9) Patients with cancer
10) Expecting mother or patients with chances to be pregnant
11) Patients who have allergies to the test drug

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Eradication rate
Secondary Outcome Measures
NameTimeMethod
Adaptation level and side-effects of drug
© Copyright 2025. All Rights Reserved by MedPath